Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Multi-Arm Study of Magrolimab Combinations in Relapsed/Refractory Multiple Myeloma
2021-001798-21Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of magrolimab in multiple myeloma (MM) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Safety run-in primary endpoints. Started Nov 2021; status: completed.
02
Drugs
magrolimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-001798-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001798-21.